Drug Discovery Outsourcing Market Set To Grow To Over $21bn In 2017

09 August 2017
Pharma

Visiongain has launched a new pharma report Drug Discovery Outsourcing Market Forecast 2017-2027: Revenue Prospects for Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening, Leading National Markets and Companies

The drug discovery outsourcing market is one of the fastest growing sectors of the pharmaceutical contract research markets. The increased costs in the discovery and development of new drugs, due in part to the high attrition rate of drug candidates in development, has driven companies to outsource part or all of their discovery process.

Contract Research Organisations (CROs) have evolved rapidly to meet the needs for the full spectrum of companies from virtual companies to large pharma. In recent years, Visiongain has observed an increasing number of alliances and partnerships between companies and CROs. This has resulted from plans to reduce the cost of discovery and from the fact that companies are increasingly requiring specialised expertise from CROs whilst seeking to accelerate the drug discovery process. The trend is showing that CROs are becoming the powerhouses behind drug discovery.

The lead Visiongain report analyst for this report commented; “Drug discovery outsourcing will continue to experience healthy growth throughout the forecast period. This growth stems from an increasing demand for outsourced services as pharmaceutical companies become more apt to share the burden of high-risk/high-reward novel drug discovery. This shift has been brought about by increased costs in the discovery and development of new drugs, due in part to the high attrition rate of drug candidates in development, driving companies to outsource part or all of their discovery process and will ultimately lead to more globalized interconnected routes of drug discovery.”

The Drug Discovery Outsourcing market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the drug discovery outsourcing market include Albany Molecular Research (AMRI), Aptuit, Charles River Laboratories, Covance, Cyprotex, Domainex, Evotec, GenScript, Pharmaceutical Product Development (PPD), Quintiles, Selcia, VivaBiotech, WIL Research Laboratories and WuXiAppTec

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Clinical Trial Supply and Logistics market for pharma set to grow to $26bn by 2024” says new Visiongain report

Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs.

18 April 2019

Read

“Global Biosimilar Drugs market set to grow to $57bn by 2023” says new Visiongain report

The biosimilars landscape will likely to undergo great changes in the future as the market starts to mature.

17 April 2019

Read

“Global Drug Discovery Outsourcing market set to grow to $45bn by 2024” says new Visiongain report

A major restraint in the global drug discovery outsourcing market comes from the fact that it is quickly becoming saturated, with many contract research organisations offering poorly differentiated services.

16 April 2019

Read

“Global Dermatological Drugs market set to grow to $36bn by 2024” says new Visiongain report

The dermatological drugs market has in the past been the domain of small and medium-sized pharma companies specialising in dermatology and perhaps a few other therapeutic areas.

15 April 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1